Nivalis Therapeutics Overview
- Founded
- 2007
- Status
- Acquired/Merged
- Latest Deal Type
- 2ndary - Open
- Investors
- 1
Nivalis Therapeutics General Information
Description
Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.
Contact Information
Website
www.nivalis.com
Formerly Known As
N30 Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Office
- 3122 Sterling Circle
- Suite 200
- Boulder, CO 80301
- United States
Nivalis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Secondary Transaction - Open Market | 12-Apr-2018 | Completed | Generating Revenue/Not Profitable | |||
| 12. Merger/Acquisition | 24-Jul-2017 | 0000 | 00000 | 0000 | Completed | Profitable |
| 11. Secondary Transaction - Open Market | 22-Mar-2017 | 00000 | Completed | Clinical Trials - Phase 1 | ||
| 10. IPO | 17-Jun-2015 | 0000 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 9. Early Stage VC (Series 2) | 24-Nov-2014 | 0000 | 00000 | 000.00 | Completed | Generating Revenue |
| 8. Later Stage VC (Series E) | 31-Jul-2012 | 000 | 000.00 | 00000 | Completed | Pre-Clinical Trials |
| 7. Later Stage VC (Series D) | 000.00 | 000.00 | 000.00 | Completed | ||
| 6. Debt - General | 31-Dec-2011 | 00.00 | 0000 | Completed | Generating Revenue | |
| 5. Debt - General | 31-Mar-2011 | $2.39M | $59.5M | Completed | Generating Revenue | |
| 4. Later Stage VC (Series C2) | $20M | $57.1M | 00000 | Completed |
Nivalis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 2 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00.00 | 00.000 | |
| Series 1 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00.000 |
Nivalis Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the
Biotechnology
Boulder, CO
00000
00000000000
00000000
dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
0000000000000
Lexington, MA
00
As of 0000
00000
00000000
00000
0000000
illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000000
Morristown, NJ
000
As of 0000
00000
0000
0000-00-00
000000000000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialNivalis Therapeutics Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pulmatrix | Formerly VC-backed | Lexington, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Private Equity-Backed | Morristown, NJ | 000 | 00000 | 000000000000 | |
| 00000000 000000000 | Corporate Backed or Acquired | Warrington, PA | 00 | 00000 | 00000000 | 00000 |
| 000000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | La Jolla, CA | 00 | 00000 | 000000&0 | 00000 |
Nivalis Therapeutics Patents
Nivalis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170281612-A1 | Methods for the treatment of cystic fibrosis | Abandoned | 08-Oct-2014 | 000000000 | |
| EP-3204010-A1 | Methods for the treatment of cystic fibrosis | Withdrawn | 08-Oct-2014 | 000000000 | |
| US-20140113945-A1 | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents for liver toxicity | Abandoned | 05-Jul-2011 | 0000000000 | 0 |
| US-20140094465-A1 | Compounds as s-nitrosoglutathione reductase inhibitors | Abandoned | 10-Jun-2011 | 0000000000 | 00 |
| JP-2014506875-A | Novel substituted bicyclic aromatic compounds as s-nitrosoglutathione reductase inhibitors | Granted | 16-Dec-2010 | A61K31/47 | 0 |
Nivalis Therapeutics Executive Team (16)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mitchell Gold MD | Chief Executive Officer | ||
| David Rodman MD | Chief Medical Officer & Vice President of Discovery |
Nivalis Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Evan Loh MD | Self | Director | 000 0000 |
| John Moore JD | Self | Board Member | 000 0000 |
| Robert Conway | Self | Director | 000 0000 |
Nivalis Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Bridger Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Jennison Associates | Asset Manager | Minority | 000 0000 | 000000 0 | |
| RA Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Rock Springs Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Sabby Management | Venture Capital | Minority | 000 0000 | 000000 0 |
Nivalis Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 18-Apr-2017 | 0000000 00 | Pharmaceuticals |
Nivalis Therapeutics Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 000000 0000 | 18-Apr-2017 | 0000000 000000 | Completed |
|